Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis - Wikidata - awgldk - TriplyDB

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

http://www.wikidata.org/entity/Q34480471

about

Update in Cystic Fibrosis 2014 Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences New and emerging targeted therapies for cystic fibrosis Advancing clinical development pathways for new CFTR modulators in cystic fibrosis Targeted therapies to improve CFTR function in cystic fibrosis Early pulmonary inflammation and lung damage in children with cystic fibrosis Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms Paediatrics: messages from Munich Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.CFTR Modulators for the Treatment of Cystic Fibrosis.Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.A call for accurate pharmacogenetic labeling: telling it like it is Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation PharmGKB summary: very important pharmacogene information for CFTR Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor.Ivacaftor Therapy in CF Patients: Single Center Experience.Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time.The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.Pilot evaluation of ivacaftor for chronic bronchitis.Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis.In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomography.Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation Novel outcome measures for clinical trials in cystic fibrosis New and Emerging Treatments for Cystic Fibrosis.Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.

P2860

Q22306307-BF855404-ED69-4135-8E20-DD6485F49EFE Q26747210-0538515F-6207-4EAD-B173-42EA25992725 Q26749278-1634B078-8296-44F4-BF0A-38EFEF3B4C0A Q26768266-CA946C7E-895D-4924-BB60-B1F50CCA3A4A Q26781441-CCA7F2B3-D633-41E4-8020-6AC1AD0806DF Q27027040-BFD81FBD-7889-433F-96C8-0D8D0BCC877A Q28071357-C871B1C3-D858-4E54-BB71-78C77813EE41 Q28073996-CC740759-7BE3-4203-9301-FEC7A0C0D852 Q28077411-0D874A2A-B540-4401-AF38-3ED08A6FDDC2 Q28596759-8A85B29A-4EED-4F57-BFC0-32E63E20D858 Q33551857-3F682585-1F1F-4446-8DA2-2E550AFC6C89 Q33865292-6B4D8447-1236-47BA-AF12-AA0F083F3D5B Q33916434-DD533663-443D-47F6-9A22-F71F600683EE Q33920366-6B0521DC-FFD8-49DB-B70B-EE7CA43FA680 Q34496122-33E27D2C-26AF-43E4-A74A-D37B655E3FC5 Q34602508-1825CB11-CA8C-41F4-A5BA-21894BC2FA9F Q35073075-C7442A1A-DD4A-4947-910E-98F3F7775E35 Q35108743-D22F7660-516C-4225-B06D-D8C57E71113D Q35127240-60A21A15-C5CD-4A75-8E28-D05100834374 Q35326173-D2EC37BA-F10E-4272-AB08-0EC3D791E428 Q36054346-679DDB83-85F3-4D5A-9AD0-FF4A91FF3473 Q36112663-17F2708B-FFE8-46AB-851D-7B2D5C2E7A8F Q36215326-F8B57399-6144-489E-89FD-CF83E121AAE1 Q36268539-9D0537C4-BDDD-4865-9E68-5ECD5A8BD2A1 Q36433196-C3577D10-B872-45E9-9B74-0EBC5AC79EA2 Q36609344-CB4DDC8D-C1C0-4EF5-B8BD-88EB04FB6863 Q36865792-0FE2C712-CD30-4095-94B0-D13B8DA653CE Q36976621-C59610F8-7840-4591-B150-DA9C9DE7FC60 Q37028545-B46AF14F-6D54-402D-B22C-802059032920 Q37065065-7A8A9FB3-FB07-446E-A33A-BAC0C643DC83 Q37103151-6761506B-38E3-4DD1-9D57-F27494BB8ABE Q37161413-F97C24EA-FBEE-4FCD-9F42-35384BAAB5D8 Q37199853-B6453328-FE46-4367-9BF4-1FD17CA5238A Q37241561-479090D4-8C8C-48BC-A63D-81FC3226F3A7 Q37241563-DCD0472A-D359-430A-B90A-ED25080AB97E Q37602780-76E24CAE-CBC0-40DB-A2CC-41F9B65F00B6 Q37605093-70DD3872-CC80-4C8A-8DFA-EE9A64502631 Q38340406-DCFFB49E-4C18-482D-9A8A-F7408FDF7D84 Q38532426-EB28A054-C404-4BCE-94D6-EB76B6CDA59A Q38533943-4AAF96E5-196A-45C9-BFBF-1A3C0BEB4C75

P2860

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

http://www.wikidata.org/entity/Q34480471

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@ast

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@en

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@nl

type

label

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@ast

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@en

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@nl

prefLabel

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@ast

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@en

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@nl

P1433

Q34480471-D6164F29-D6B6-4F1F-B57C-8964CB48B0CE

P1476

Q34480471-519E2CCB-EFA7-49A0-A1FD-6AA1C845BF3E

P2093

Q34480471-0451D2DC-0655-4256-8D53-92A8E202B48F

Q34480471-1515A26A-27B4-4B0A-9B85-E13B03A88BC5

Q34480471-18791172-3B2A-4222-8628-A41DFEC03DCA

Q34480471-1EC62D4E-9E7B-4A39-8534-AF79CEFBD749

Q34480471-3CDA623F-CD63-4293-9EF1-787C0AC07130

Q34480471-55D322B1-BC2F-40AD-B171-86CF4E50487E

Q34480471-578F6E1F-FB77-4300-B4D3-37A4ABDEEA62

Q34480471-6833666A-E5FE-42AA-86F7-82C904D8FF61

Q34480471-9F43B1DF-3232-42AA-950E-162C357E6C98

Q34480471-C4BE9BEA-2A23-49BD-BF55-F16F0F1DF5A3

P2860

Q34480471-0202CAFF-DE72-4949-87B2-D9D4B1F2B901

Q34480471-0CA51B2F-6075-4E1D-8EB3-35D602C15818

Q34480471-1280CFB3-B3D7-4F55-87E6-021E1874DBE6

Q34480471-246DED95-FD4E-4B02-9C4C-67CFE9FEF906

Q34480471-28E9B3E4-25CC-4C2D-AB4D-9C562E15CE95

Q34480471-2C124EC3-D25D-49C7-BA80-3F17AEEE98DE

Q34480471-402694A4-98EC-4591-94CA-3321006BC8D5

Q34480471-41B94572-81B9-4CA0-929A-67B525CD1C90

Q34480471-48B827D5-846E-46E6-A0FE-3105E00B50BF

Q34480471-4A501C5C-5A81-4B53-BB4C-83F8B237F285

P304

Q34480471-B40C8744-23C0-4872-B445-57D5A06269C4

P31

Q34480471-BD99B710-44D3-470D-A706-641BD6445DB1

P356

Q34480471-21E005D0-0ECF-42CC-AB82-E2077EF88654

P407

Q34480471-1B1C6A79-26CE-4B0B-B227-703206FE1414

P433

Q34480471-A74179BB-437C-4400-A7CE-0051F920515F

P478

Q34480471-746D7636-618D-4052-94C4-7AA3631EABCE

P577

Q34480471-02333E9D-3C61-4706-84E6-BDB559140CD4

P698

Q34480471-AF145038-0B89-43FE-956A-2A8801F9CE56

P921

Q34480471-19B58E6A-050B-43DC-BD16-40AE4A0DC425

Q34480471-2E77A161-B3E5-4543-8CA1-7291F93681F6

P932

Q34480471-A4B2A44F-8698-418C-8EE9-7BF5E7D09D4B

P356

RCCM.201404-0703OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis

@en

P2093

Bonnie W Ramsey

http://www.w3.org/2001/XMLSchema#string

Daniel Gelfond

http://www.w3.org/2001/XMLSchema#string

Drucy Borowitz

http://www.w3.org/2001/XMLSchema#string

Elizabeth Joseloff

http://www.w3.org/2001/XMLSchema#string

GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network

http://www.w3.org/2001/XMLSchema#string

Jill M Van Dalfsen

http://www.w3.org/2001/XMLSchema#string

Nicole Mayer-Hamblett

http://www.w3.org/2001/XMLSchema#string

Scott D Sagel

http://www.w3.org/2001/XMLSchema#string

Scott H Donaldson

http://www.w3.org/2001/XMLSchema#string

Sonya L Heltshe

http://www.w3.org/2001/XMLSchema#string

P2860

Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients

Spirometric reference values from a sample of the general U.S. population

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

Cystic fibrosis

Cystic fibrosis

Role of epithelial HCO3⁻ transport in mucin secretion: lessons from cystic fibrosis

Standardization of Spirometry, 1994 Update. American Thoracic Society

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis

Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype.

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

P304

175-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201404-0703OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

190

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24927234

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

transmembrane protein

P932

4226057

http://www.w3.org/2001/XMLSchema#string